Our CELT-331 product is a potent and selective hCB2 fluorescent ligand that shows a high affinity and selectivity for hCB2 receptor over hCB1 receptor. It has a Ki value of 75.9 nM for hCB2 receptor in radioligand binding assay. CELT-331 is suitable for HTRF binding assays as a valid alternative to radioligand binding assays. It is available in a 10 µg vial that allows for the preparation of 150 mL of 100 nM working solution to test CB2R. CELT-331 is designed to allow for cell visualization in fluorescence microscopy, confocal, and high-content system experiments and is potentially suitable for other fluorescence-based assays.
10 µg vial can be used to prepare 75.78 µL of a 100 µM stock solution, providing enough volume for 7 assays at a working concentration of 100 nM.
Please note that the required concentration may vary depending on the specific assay design.
476,00€
In stock
10 µg vial can be used to prepare 87.10 µL of a 100 µM stock solution, providing enough volume for 8 assays at a working concentration of 100 nM.
Please note that the required concentration may vary depending on the specific assay design.
476,00€Product on backorder. Contact us at info@celtarys.com for an estimated delivery date.
10 µg vial can be used to prepare 72.58 µL of a 100 µM stock solution, providing enough volume for 7 assays at a working concentration of 100 nM.
Please note that the required concentration may vary depending on the specific assay design.
476,00€ View more
10 µg vial can be used to prepare 78.30 µL of a 100 µM stock solution, providing enough volume for 7 assays at a working concentration of 100 nM.
Please note that the required concentration may vary depending on the specific assay design.
476,00€ View more
10 µg vial can be used to prepare 95.03 µL of a 100 µM stock solution, providing enough volume for 9 assays at a working concentration of 100 nM.
Please note that the required concentration may vary depending on the specific assay design.
476,00€ View more

PERTE SALUD Proyecto Nº: IDI-2025-0751
Título: TERAPIAS AVANZADAS EN INMUNOONCOLOGÍA: UNA ESTRATEGIA INNOVADORA
BASADA EN LA DEGRADACIÓN DIRIGIDA DE GPCR EN EL EJE ADENOSINÉRGICOS

EIC Pathfinder; Project name: Unisens; Universal GPCR Activity Sensor for Next Generation Drug Discovery



Esta entidad fue beneficiaria de las ayudas para la ejecución de acciones de promoción exterior de las empresas gallegas. El objetivo principal de estas ayudas es incentivar la realización de acciones de promoción exterior generadoras de ventajas competitivas. El resultado que se pretende conseguir es el impulso de las pymes y sus productos y servicios, aumentando el número de empresas de base exportadora.

Celtarys Research is beneficiary of a WomenTechEU grant supporting deep-tech start-ups led by women





Principia 2021 Program
Celtarys staff has been funded by the Xunta de Galicia within the framework of the PRINCIPIA 2021 Program of the Galician Innovation Agency (GAIN)
InnovaPEME Program
Celtarys Innovation Plan has been funded by the InnovaPEME 2022 program of the Galician Innovation Agency (GAIN)



Bonos de Innovación de Celtarys Research (026)
Para promover o desenvolvemento tecnolóxico, a innovación e unha investigación de calidade. Esta operación está financiada pola Xunta de Galicia, a través de axudas concedidas pola Axencia Galega de Innovación, dentro do programa de axudas a empresa Bonos de innovación 2022.




Celtarys Research is part of the public-private consortium developing the project PREDICTEAM
New prognostic quantitative biomarker assays for predicting patient response to immune checkpoint inhibitor (ICI) treatment





NEOTEC · CDTI — Ministerio de Ciencia e Innovación




The Project ‘New chemical conjugation technology for therapeutic targets’ has been founded by CDTI under its program NEOTEC. The NEOTEC program objective is supporting the establishment and consolidation of technology-based enterprises. A technology-based company (EBT) is a company whose activity focuses on the exploitation of products or services that require the use of technologies and knowledge developed since the research activity. The EBT base their business strategy or activity in the intensive domain of scientific and technical knowledge. Budget awarded: 416.177€ | Execution dates: 1/1/2023 – 31/03/2024
Avenida de Barcelona, 7
15706, Santiago de Compostela
A Coruña (Spain)